Hepatotoxicity characterized by microvesicular steatosis (MVS) is characterized by an abnormal accumulation of numerous small cytoplasmic lipid droplets in hepatocytes. Fulminant or progressive cases of microvesicular steatosis may lead to liver failure and death. Experimentally, shortchain carboxylic acids are known to induce microvesicular steatosis. The identification of gene changes that correlate with MVS concomitant with biochemical and histological indices could provide a better understanding of how this toxicity occurs as well as biomarkers that could be used to avoid this toxicity in the future. Sprague-Dawley rats were dosed days with cyclopropane carboxylic acid (CPCA) a short-chain fatty acid that can induce microvesicular steatosis, and with butyrate, a short chain fatty acid that served as a negative control. CPCA initiated microvesicular steatosis while butyrate did not. In addition, CPCA inhibited beta-oxidation in a concentration-dependent manner in vitro and caused a reduction in mitochondrial respiration ex vivo; no inhibition was evident with butyrate. Microarray results showed that gene expression changes with CPCA resulted in regulation of genes involved in beta-oxidation, as well as other genes associated with mitochondrial function. Overall, these results support altered hepatic mitochondrial function as a mechanism of the toxicity induced by a short-chain fatty acid and may provide potential biomarkers for this toxicity.
INTRODUCTION
Microvesicular steatosis (MVS) 1 is a severe pathology of the liver associated with a wide range of diseases, toxins, and drugs (Rehnmark et al., 1998) . The hallmark of MVS is a particular form of fat accumulation characterized by the abnormal appearance of numerous small cytoplasmic lipid droplets (fatty vacuolation) in hepatocytes (Reid, 2001) . Unlike the more common macrovesicular form, the microvesicular variant is considered to be more life-threatening, and is associated with clinical conditions such as Reye's Syndrome, Jamaican vomiting sickness, alcoholic fatty liver of pregnancy, and congenital beta-oxidation deficiencies (Pessayre et al., 1999) . Although not completely understood, it is believed that an underlying factor occurring in all of these conditions involves a deficit in mitochondrial function (Jaeschke et al., 2002) .
In addition to the disorders mentioned before, microvesicular steatosis is a toxicity observed with a number of pharmaceutical agents (Pessayre et al., 1999) and this toxicity can be particularly challenging in drug discovery, since it can take several days or weeks to manifest in animal models. Clearly, an understanding of the mechanism underlying the toxicity, as well as the identification of biomarkers would be extremely beneficial in identifying agents that have this safety liability.
Microarray technology, which allows one to analyze gene expression changes for thousands of genes in a single experi-ment, has been gaining widespread application in toxicology. Several studies have shown that this technique can be used to identify the molecular events that underlie the mechanism(s) of toxicity of xenobiotics (Holden et al., 2000; Harries et al., 2001; Reilly et al., 2001; Waring et al., 2002) . We have previously shown that compounds of differing chemical classes cluster by mechanism of toxicity in both in vivo (Bulera et al., 2001; Thomas et al., 2001; Waring et al., 2001b) and in in vitro systems (Burczynski et al., 2000; Waring et al., 2001a) . In addition, several studies have identified early gene changes that can serve as biomarkers for a particular type of toxicity (Thomas et al., 2001; Hamadeh et al., 2002) .
In this study, microarray technology was applied to identify gene changes associated with microvesicular steatosis. To that end, male, Sprague-Dawley rats were treated with cyclopropane carboxylic acid (CPCA). Little is known concerning the toxicity associated with this compound in rats, although it has been shown to impair beta-oxidation in rabbit and human hepatocytes (Ulrich et al., 1998) . Rats were also treated with butyrate, a short-chain fatty acid that is structurally similar to CPCA and has not been associated with mitochondrial impairment (Figure 1 ). Gene expression, clinical pathology, histology, and mitochondrial respiration were assessed after treatment. The results show that CPCA inhibited mitochondrial function both in vitro and in vivo. Furthermore, the gene expression results correlated with histopathology and clinical chemistry findings, and identified genes that may be associated with the mechanism underlying microvesicular steatosis.
METHODS

Materials
Sprague-Dawley rats (225-275 g) were obtained from Charles River (Portage, MI). Adenosine diphosphate, 
In vitro Experiments
Sprague-Dawley rat hepatocytes were isolated as previously described (Elliget and Kolaja, 1983) . Cytotoxicity of the compounds was evaluated in suspension by propidium iodide uptake after incubation with vehicle or test article. No cytotoxicity was noted at concentrations up to and including 1 mM by either of the compounds out to 4 hours of treatment (data not shown). Hepatic mitochondria were isolated by differential centrifugation as described previously (Radeva-Domuschieva et al., 1986) . Beta-oxidation was measured in hepatocytes in suspension and hepatic mitochondria isolated from naïve rats by following 14 C (U) palmitate turnover as described by Otto et al. (1985) . Cells and mitochondria were treated at concentrations up to 1 mM. The cells were incubated at 2 × 10 6 cells per ml with vehicle or test article in phenol-red-free modified DMEM supplemented serum-free medium at 37 • C in a shaking water bath for 1 hour. Mitochondria, suspended at 1 mg/ml (as determined by Bradford assay, BIORAD) in assay buffer were incubated for 20 minutes in the presence of vehicle or test article (Otto et al., 1985) . After incubation with compounds, radiolabel was added and the reaction was quenched with perchloric acid 10 minutes after addition of substrate. The reactions were hexane extracted and acid precipitable material was counted using a Microbeta scinitillation detector (Perkin Elmer). All in vitro experiments were repeated 3 times with independent isolations; the data is a summary of all experiments.
In vivo Experiment
Male Sprague-Dawley rats were administered vehicle or test article in a dose volume of 10 ml/kg: CPCA was dosed at 500 mg/kg/day and butyrate at 700 mg/kg/day, intraperitoneally for 1 or 3 days. Animals were fasted and sacrificed approximately 24 hours after the final dose. Compounds were formulated in sterile saline to a final pH of 6-7 with 1N NAOH. Vehicle treated rats received saline instead of test article. Toxicity was evaluated by clinical pathology and histology. Serum from animals was analyzed on an Abbott Aeroset (Abbott Diagnostics). A section of liver from each animal was fixed in neutral buffered formalin and processed and stained with H&E. Slides were graded for MVS from minimal to severe. Hepatic mitochondria were isolated from vehicle and treated animals and oxygen consumption was measured using a Strathkelvin oxygen system (Strathkelvin Inc. Glascow, Scotland). Respiration was assessed by measuring oxygen consumption after the addition of glutamate and malate (G/M) at 5 mM or succinate (SC) at 5 mM with rotenone at 1 µg/ml followed by ADP at 0.3 mM. Mitochondria were then uncoupled by the addition of 2,4-dinitrophenol to a final concentration of 25 µM. The respiratory control ratio (RCR) was calculated by dividing the state III by state IV (post ADP depletion) oxygen consumption rates. Each mitochondrial fraction was measured in triplicate for each substrate tested. For all biochemical analyses statistics were done using Sigma Stat software (SPSS Inc., Chicago, IL, Version 2.03). One-way ANOVA was applied to the data followed by a Bonferroni multiple comparison test. All changes with a p-value less than 0.05 were considered statistically significant.
Total RNA was quantitated by absorbance and the RNA A260/A280 ratios always exceeded 2.0. Then, 15 µg of total RNA from liver was analyzed on rat genome U234A Affymetrix chips (Santa Clara, CA). The protocol for reverse transcription of the RNA is as per the kit from Invitrogen (c/n 18090-019) with the exception that the primer used was a modified T7 primer with 24 thymidines at the 5' end. Following this, labeled cRNA was synthesized according to manufacturers' instructions for the cDNA using the ENZO RNA Transcript Labeling Kit (c/n 900182). Approximately 20 µg of cRNA was then fragmented in 40 mM Tris acetate, pH 8.1, 100 mM KOAc, and 30 mM MgOAc solution at 94 • F for 35 minutes. Data was analyzed using Resolver version 3.1 (Rosetta Inpharmatics, Kirkland WA).
RESULTS
CPCA significantly inhibited beta-oxidation in a concentration dependent manner in both rat hepatocytes and isolated mitochondria ( Figure 2 ). In isolated mitochondria, the inhibition of beta-oxidation by CPCA was significantly FIGURE 2.-The effects of CPCA and BTR on cellular and mitochondrial beta-oxidation in vitro. Data represent 3 independent experiments and are expressed as percent control ± standard deviation relative to DMSO vehicle at 1% (v/v). Control rates for palmitate oxidation were 1.2 nmoles palmitate oxidized/ min/mg protein in hepatocytes and 3.6 nmoles palmitate oxidized/min/mg in isolated hepatic mitochondria. * Indicates that the values are significantly different from vehicle control (100 ± 5%), p < 0.05. decreased at all concentrations tested, while in isolated hepatocytes beta-oxidation and was significantly decreased at the 300 µM and 1mM concentrations only. In contrast to this, the negative control, butyrate, had no effect in either system. In order to examine the effects of CPCA and butyrate in vivo, male Sprague-Dawley rats were dosed with these compounds for 1 or 3 days. Histopathology, clinical chemistry, biochemical, and microarray analysis data were collected from the study.
Changes in clinical chemistry after treatment are summarized in Table 1 . No significant changes in clinical chemistry were observed after vehicle or with butyrate. Increased levels of circulating glucose were noted in all 3 animals after 1 dose of CPCA but other clinical chemistry changes with CPCA treatment were confined to Day 3. All CPCA animals on that day had elevated blood urea nitrogen values. One rat in the CPCA treated group on Day 3 had elevated ALT, AST, and ALP activities; interestingly this animal had the most pronounced MVS as well. For CPCA, leukocyte and neutrophil counts were mildly low in 2 of the animals on Day 1 and in treated animals on Day 3 (data not shown). In addition, there was an increase in serum glucose levels on Day 3.
CPCA-treated animals showed incidences of hepatocellular microvesicular vacuolation (Table 2) . CPCA caused a minimal microvesicular fatty vacuolation in 3/3 animals on Day 1 and a mild to moderate microvesicular fatty vacuolation in 3/3 animals on Day 3. While this morphological change was subtle, it was considered treatment related and an early form of microvesicular steatosis. In contrast to this, there were no observations of fatty vacuolation with butyrate at either Day 1 or Day 3. Slight hepatocellular vacuolation was observed in 1/3 vehicle treated animal on Day 1. This observation was considered to be extremely subtle and within normal limits of variation and therefore not thought to be treatment related. Complex I (glutamate malate, GM), Complex II (succinate, SC) as well as mitochondrial uncoupling were assessed by measuring oxygen consumption in isolated mitochondria from treated animals ex vivo. Respiration data from mitochondria isolated from treated animals are shown in Figure 3 . No changes in respiration were observed in the butyrate treated animals on either Day 1 or 3 with either GM or SC. In contrast to this, a significant decrease in GM dependentrespiration was observed in the CPCA-treated animals on Day 1, and in both GM and SC dependent respiration on Day 3. The observed decrease in SC dependent complex II activity in animals treated with CPCA on Day 3 could be secondary to inhibition of GM complex I respiration. No effect on DNP dependent uncoupling was noted with CPCA treatment (data not shown). These data clearly show that treatment with CPCA causes an inhibition of mitochondrial respiration, suggesting a mechanism underlying the cause of the microvesicular steatosis.
Microarray analysis was performed on RNA from individual rats treated with CPCA and butyrate. Figure 4 shows an unsupervised K-means cluster of the results. The expression profiles fall into three clusters. Cluster 1, which shows the most gene regulation, is comprised of expression profiles from 2 of the 3 animals treated with high dose CPCA at Day 3. Cluster 2, which shows a number of similarities to Cluster 1, is composed of the expression profiles from the 3 animals treated with CPCA at Day 1, and the remaining animal treated with CPCA on Day 3. The remaining cluster, which show substantially fewer gene expression changes, are composed of expression profiles from animals treated with butyrate at Day 1 or Day 3.
Several pathways involved in mitochondrial respiration or other mitochondrial functions were affected by treatment with CPCA, particularly on Day 3. Genes involved in fatty acid beta-oxidation, gluconeogenesis and apoptosis were all significantly regulated by treatment with CPCA ( Figure 5A and B) (Dahlquist et al., 2002; Doniger et al., 2003) . The majority of these genes were not regulated by butyrate.
Along with genes involved in beta-oxidation, gluconeogenesis and apoptosis, a number of other genes were regulated by CPCA on both Day 1 and Day 3 that were not regulated by butyrate. Some of these genes are shown in Table 3 .
DISCUSSION
This experiment was designed to assess gene expression after dosing with CPCA and butyrate while following clinical pathology, histology, and mitochondrial respiration. In this way the relative sensitivity of the gene expression response was directly compared to more traditional endpoints. We dosed intraperitoneally to obviate any differences in absorption of the compounds.
We chose to evaluate microarray analysis in a model of microvesicular steatosis (MVS) and its early form mi- crovesicular vacuolation for several reasons. Steatosis is a fairly common response to xenobiotics and is often problematic in the discovery and development of new drugs. Vacuolation is also often a rather subtle and common finding and can be difficult to interpret due to its multiple causes Vol. 32(Suppl. 2), 2004 MICROARRAY ANALYSIS OF CPCA TOXICITY 23 FIGURE 4.-Heat map showing a K-means cluster of expression profiles generated from rats treated with CPCA or butyrate for 1 or 3 days. The profiles were grouped into three clusters, while the genes were grouped into 5 clusters. The genes shown were regulated by 2-fold or more in at least one experiment with a p-value less that 0.01. Genes shown in red are upregulated, genes shown in green are downregulated, and genes shown in black were not changed in expression.
including steatosis, glycogen depletion and phospolipidosis. Microvesicular steatosis, a form of steatosis, is associated with Reye's Syndrome and hepatic failure clinically and it is therefore important to divine a mechanism for this pathology where observed as well as to provide biomarkers for avoiding it.
Furthermore, steatosis can be a particularly challenging toxicity to identify using traditional toxicology endpoints. In our study, for instance, the pathology observed was very minimal and just at the borderline for biological relevance. Previous studies using other short-chain fatty acids have demonstrated the difficulty in reproducing the model of microvesicular steatosis within and between laboratories (Lewis et al., 1982; Kesterson et al., 1984; Losher et al., 1992) . One possibility why this toxicity is so difficult to observe is the fact that the liver has excess capacity for beta-oxidation and respiration and until this reserve is overwhelmed no toxicity will be noted (Zimmerman, 1999) . This could also explain the idiosyncratic response often observed with this lesion, since exceeding this reserve could require a combination of xenobiotic treatment and underlying host factors such as diet and metabolism (Ulrich et al., 2001) .
We observed inhibition of beta-oxidation in whole cells as well as in isolated mitochondria with CPCA, but not with butyrate. As might be expected the inhibition in the whole cell was milder than was observed in the organelle suggesting some protection of the cell membrane. The whole cell data indicate that the effect of CPCA on the mitochondria is direct and not an artifact of the subcellular organellar system. Cells in suspension were used in this study because they are aerobic and have more measurable mitochondrial activity than cells in culture, which are glycolytic. While this assay can serve as a useful surrogate for rank ordering of a compounds effect on beta-oxidation, extrapolating the in vitro data to the whole animal is difficult if not impossible. Ultimately, data showing a mitochondrial effect in vivo is needed to substantiate the in vitro assay.
In order to observe the effects of a short-chain fatty acid on mitochondria function in vivo, we measured the effects on mitochondrial respiration in rats treated with CPCA, and butyrate. Significant decreases in respiration were observed in the rats using GM or SC by 3 days with CPCA but not butyrate. For CPCA, this decrease in RCR was primarily due to a drop in State III oxygen consumption, although a mild increase (uncoupling) in State IV was also noted relative to controls. These results were similar to the effects of CPCA observed in vitro in naïve rat hepatic mitochondria at 1 mM (data not shown). A decrease in GM but not SC driven respiration was evident at 1 day for the CPCA treated animals. While respiration can and has been used to assess compounds for this toxicity it is extremely labor intensive and can be difficult to carry out in a necropsy setting. Expression data provides another means of generating mechanistic data demonstrating mitochondrial involvement in toxicity.
For the majority of the rats treated with CPCA that showed some pathology indicating steatosis, the gene expression results correlated well with the pathology. Mitochondrial dysfunction likely involves inhibition of dehydrogenases in betaoxidation and Krebs cycles, inhibition of respiration, a drop in complex IV content or membrane effects, and sequestration of carnitine and coenzyme A (Zimmerman, 1999) . In addition, mitochondrial damage often leads to signaling of 24 WARING ET AL. TOXICOLOGIC PATHOLOGY (Dahlquist et al., 2002; Doniger et al., 2003) . apoptotic pathways involving Bcl and Bax (Lim et al., 2002) . The gene expression analysis showed that genes involved in mitochondrial beta-oxidation were downregulated by CPCA, especially by Day 3. In addition, CPCA upregulated a number of genes involved in apoptosis, including c-myc, cytochrome c and Bax. These changes appear to be associated with the histopathology, since butyrate did not regulate these genes.
A number of other gene families were regulated exclusively by CPCA in this study. For instance, genes for beta globin and alpha-2 globin were downregulated with CPCA treatment on both Day 1 and Day 3. This corresponds the decrease in serum globulin levels seen on Day 3 with CPCA. In addition, genes involved in cell cycle control were strongly upregulated by CPCA at Day 3 (Table 3) . Previous research has shown that animal models for steatosis display increased liver weights, which is accompanied by hepatocyte proliferative activity (Yang et al., 2001) . Importantly, these gene changes were seen despite the fact that no increase in liver weights was observed. Possibly, an increase in liver size would have been seen after more days of treatment. Thus, genes involved in cell cycle regulation, coupled with genes involved in apoptosis, mitochondrial function and gluconeogenesis, might serve as early gene markers for microvesicular steatosis.
These results support the role of mitochondrial dysfunction in the toxicity of short-chain fatty acids. In particular the strong correlation between the pathology, biochemistry and the gene expression gives credence to the data's utility in ferreting out the mechanism of unknown compounds. Genes have been identified that may serve as markers for microvesicular steatosis. Further studies characterizing some of the gene changes observed in this study are presently underway.
